Raras
Buscar doenças, sintomas, genes...
Lipodistrofia genética
ORPHA:98305CID-11 · LD27.6DOENÇA RARA

Um caso de lipodistrofia causado por uma modificação genômica herdada em um indivíduo.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Um caso de lipodistrofia causado por uma modificação genômica herdada em um indivíduo.

Publicações científicas
19 artigos
Último publicado: 2025 Oct 10
🏥
SUS: Sem cobertura SUSScore: 0%
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🦴
Ossos e articulações
64 sintomas
😀
Face
47 sintomas
🧠
Neurológico
38 sintomas
💪
Músculos
37 sintomas
🧬
Pele e cabelo
35 sintomas
📏
Crescimento
34 sintomas

+ 185 sintomas em outras categorias

Características mais comuns

Calvária espessada
Comprometimento cognitivo
Deterioração psicomotora progressiva
Anormalidade do sistema complemento
Distrofia ungueal
Morfologia anormal da ponta do dedo
528sintomas
Sem dados (528)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 528 características clínicas mais associadas, ordenadas por frequência.

Calvária espessadaThickened calvaria
Comprometimento cognitivoCognitive impairment
Deterioração psicomotora progressivaProgressive psychomotor deterioration
Anormalidade do sistema complementoAbnormality of complement system
Distrofia unguealNail dystrophy

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2025
Total histórico19PubMed
Últimos 10 anos17publicações
Pico20245 papers
Linha do tempo
2025Hoje · 2026🧪 2004Primeiro ensaio clínico📈 2024Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

18 genes identificados com associação a esta condição.

PLIN1Perilipin-1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Modulator of adipocyte lipid metabolism. Coats lipid storage droplets to protect them from breakdown by hormone-sensitive lipase (HSL). Its absence may result in leanness. Plays a role in unilocular lipid droplet formation by activating CIDEC. Their interaction promotes lipid droplet enlargement and directional net neutral lipid transfer. May modulate lipolysis and triglyceride levels

LOCALIZAÇÃO

Endoplasmic reticulumLipid droplet

VIAS BIOLÓGICAS (4)
Transcriptional regulation of white adipocyte differentiationMLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosisTriglyceride catabolismNR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose
MECANISMO DE DOENÇA

Lipodystrophy, familial partial, 4

An autosomal dominant form of lipodystrophy characterized by loss of subcutaneous adipose tissue primarily affecting the lower limbs, insulin-resistant diabetes mellitus, hypertriglyceridemia, and hypertension.

EXPRESSÃO TECIDUAL(Ubíquo)
Tecido adiposo
970.2 TPM
Adipose Visceral Omentum
542.5 TPM
Mama
309.8 TPM
Nervo tibial
39.5 TPM
Artéria coronária
30.3 TPM
OUTRAS DOENÇAS (1)
PLIN1-related familial partial lipodystrophy
HGNC:9076UniProt:O60240
AKT2RAC-beta serine/threonine-protein kinaseCandidate gene tested inAltamente restrito
FUNÇÃO

Serine/threonine kinase closely related to AKT1 and AKT3. All 3 enzymes, AKT1, AKT2 and AKT3, are collectively known as AKT kinase. AKT regulates many processes including metabolism, proliferation, cell survival, growth and angiogenesis, through the phosphorylation of a range of downstream substrates. Over 100 substrates have been reported so far, although for most of them, the precise AKT kinase catalyzing the reaction was not specified. AKT regulates glucose uptake by mediating insulin-induced

LOCALIZAÇÃO

CytoplasmNucleusCell membraneEarly endosome

VIAS BIOLÓGICAS (5)
CD28 dependent PI3K/Akt signalingVEGFR2 mediated vascular permeabilityPIP3 activates AKT signalingNegative regulation of the PI3K/AKT networkG beta:gamma signalling through PI3Kgamma
OUTRAS DOENÇAS (3)
hypoinsulinemic hypoglycemia and body hemihypertrophytype 2 diabetes mellitusAKT2-related familial partial lipodystrophy
HGNC:392UniProt:P31751
POLR3ADNA-directed RNA polymerase III subunit RPC1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalytic core component of RNA polymerase III (Pol III), a DNA-dependent RNA polymerase which synthesizes small non-coding RNAs using the four ribonucleoside triphosphates as substrates. Synthesizes 5S rRNA, snRNAs, tRNAs and miRNAs from at least 500 distinct genomic loci (PubMed:19609254, PubMed:19631370, PubMed:20413673, PubMed:33335104, PubMed:33558764, PubMed:33558766, PubMed:34675218, PubMed:35637192, PubMed:9331371). Pol III-mediated transcription cycle proceeds through transcription init

LOCALIZAÇÃO

NucleusCytoplasm, cytosol

VIAS BIOLÓGICAS (1)
Cytosolic sensors of pathogen-associated DNA
MECANISMO DE DOENÇA

Leukodystrophy, hypomyelinating, 7, with or without oligodontia and/or hypogonadotropic hypogonadism

An autosomal recessive neurodegenerative disorder characterized by childhood onset of progressive motor decline manifest as spasticity, ataxia, tremor, and cerebellar signs, as well as mild cognitive regression. Other features may include hypodontia or oligodontia and hypogonadotropic hypogonadism. There is considerable inter- and intrafamilial variability.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
19.6 TPM
Cerebelo
18.6 TPM
Pituitária
15.8 TPM
Fibroblastos
14.5 TPM
Linfócitos
12.7 TPM
OUTRAS DOENÇAS (7)
leukodystrophy, hypomyelinating, 7, with or without oligodontia and/or hypogonadotropic hypogonadismWiedemann-Rautenstrauch syndrometremor-ataxia-central hypomyelination syndromeodontoleukodystrophy
HGNC:30074UniProt:O14802
LIPEHormone-sensitive lipaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Lipase with broad substrate specificity, catalyzing the hydrolysis of triacylglycerols (TAGs), diacylglycerols (DAGs), monoacylglycerols (MAGs), cholesteryl esters and retinyl esters (PubMed:15716583, PubMed:15955102, PubMed:19800417, PubMed:8812477). Shows a preferential hydrolysis of DAGs over TAGs and MAGs and preferentially hydrolyzes the fatty acid (FA) esters at the sn-3 position of the glycerol backbone in DAGs (PubMed:19800417). Preferentially hydrolyzes FA esters at the sn-1 and sn-2 po

LOCALIZAÇÃO

Cell membraneMembrane, caveolaCytoplasm, cytosolLipid droplet

VIAS BIOLÓGICAS (1)
Triglyceride catabolism
MECANISMO DE DOENÇA

Lipodystrophy, familial partial, 6

An autosomal recessive form of lipodystrophy characterized by abnormal subcutaneous fat distribution. Affected individuals have increased visceral fat, impaired lipolysis, dyslipidemia, hepatic steatosis, systemic insulin resistance, and diabetes. Some patients manifest muscular dystrophy.

EXPRESSÃO TECIDUAL(Ubíquo)
Tecido adiposo
342.8 TPM
Adipose Visceral Omentum
231.3 TPM
Mama
146.1 TPM
Testículo
74.5 TPM
Brain Spinal cord cervical c-1
57.0 TPM
OUTRAS DOENÇAS (1)
LIPE-related familial partial lipodystrophy
HGNC:6621UniProt:Q05469
NOTCH3Neurogenic locus notch homolog protein 3Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Functions as a receptor for membrane-bound ligands Jagged1, Jagged2 and Delta1 to regulate cell-fate determination (PubMed:15350543, PubMed:14714274). Upon ligand activation through the released notch intracellular domain (NICD), it forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes of the enhancer of split locus. Affects the implementation of differentiation, proliferation and apoptotic programs (By similarity)

LOCALIZAÇÃO

Cell membraneNucleus

VIAS BIOLÓGICAS (1)
Pre-NOTCH Processing in Golgi
MECANISMO DE DOENÇA

Cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, 1

A cerebrovascular disease characterized by multiple subcortical infarcts, pseudobulbar palsy, dementia, and the presence of granular deposits in small cerebral arteries producing ischemic stroke.

EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
402.5 TPM
Aorta
222.4 TPM
Artéria coronária
208.2 TPM
Tecido adiposo
157.8 TPM
Skin Sun Exposed Lower leg
145.9 TPM
OUTRAS DOENÇAS (5)
lateral meningocele syndromemyofibromatosis, infantile, 2cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1familial partial lipodystrophy, Kobberling type
HGNC:7883UniProt:Q9UM47
CAVIN1Caveolae-associated protein 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Plays an important role in caveolae formation and organization. Essential for the formation of caveolae in all tissues (PubMed:18056712, PubMed:18191225, PubMed:19726876). Core component of the CAVIN complex which is essential for recruitment of the complex to the caveolae in presence of calveolin-1 (CAV1). Essential for normal oligomerization of CAV1. Promotes ribosomal transcriptional activity in response to metabolic challenges in the adipocytes and plays an important role in the formation of

LOCALIZAÇÃO

Membrane, caveolaCell membraneMicrosomeEndoplasmic reticulumCytoplasm, cytosolMitochondrionNucleus

VIAS BIOLÓGICAS (3)
RHOB GTPase cycleRHOC GTPase cycleRHOA GTPase cycle
MECANISMO DE DOENÇA

Lipodystrophy, congenital generalized, 4

A form of congenital generalized lipodystrophy, a metabolic disorder characterized by a near complete absence of adipose tissue, extreme insulin resistance, hypertriglyceridemia, hepatic steatosis and diabetes mellitus. CGL4 is characterized by the association of congenital generalized lipodystrophy with muscular dystrophy and cardiac anomalies. Inheritance is autosomal recessive.

OUTRAS DOENÇAS (1)
congenital generalized lipodystrophy type 4
HGNC:9688UniProt:Q6NZI2
AGPAT21-acyl-sn-glycerol-3-phosphate acyltransferase betaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Converts 1-acyl-sn-glycerol-3-phosphate (lysophosphatidic acid or LPA) into 1,2-diacyl-sn-glycerol-3-phosphate (phosphatidic acid or PA) by incorporating an acyl moiety at the sn-2 position of the glycerol backbone

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (2)
Synthesis of PAMLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
MECANISMO DE DOENÇA

Lipodystrophy, congenital generalized, 1

A form of congenital generalized lipodystrophy, a metabolic disorder characterized by a near complete absence of adipose tissue, extreme insulin resistance, hypertriglyceridemia, hepatic steatosis and early onset of diabetes. Inheritance is autosomal recessive.

OUTRAS DOENÇAS (1)
congenital generalized lipodystrophy type 1
HGNC:325UniProt:O15120
ADRA2AAlpha-2A adrenergic receptorDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Alpha-2 adrenergic receptors are G protein-coupled receptors for catecholamines that activate the G(i/o) protein pathway, thereby promoting adenylyl cyclase inhibition, ERK1/2 stimulation, and voltage-gated calcium channels suppression (PubMed:2170371, PubMed:23105096, PubMed:2568356, PubMed:35245122, PubMed:27376152). Control a variety of physiological processes, such as regulation of blood pressure, lipolysis and insulin release (PubMed:2568356, PubMed:27376152). ADRA2A and ADRA2C mediates the

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (6)
G alpha (i) signalling eventsG alpha (z) signalling eventsAdrenaline signalling through Alpha-2 adrenergic receptorAdrenoceptorsSurfactant metabolism
MECANISMO DE DOENÇA

Lipodystrophy, familial partial, 8

An autosomal dominant form of partial lipodystrophy, a disorder characterized by abnormal subcutaneous fat distribution. FPLD8 patients show selective loss of subcutaneous adipose tissue from the limbs, beginning around 13 to 15 years of age, and abnormal accumulation of subcutaneous adipose tissue in the dorsal neck and face, as well as in the posterior thoracic and abdominal regions. The disorder is associated with metabolic abnormalities, including diabetes mellitus and hyperlipidemia.

OUTRAS DOENÇAS (1)
lipodystrophy, familial partial, type 8
HGNC:HGNC:281UniProt:P08913
CIDECLipid transferase CIDECDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Lipid transferase specifically expressed in white adipose tissue, which promotes unilocular lipid droplet formation by mediating lipid droplet fusion (PubMed:18334488, PubMed:19843876, PubMed:20049731, PubMed:23399566, PubMed:30361435). Lipid droplet fusion promotes their enlargement, restricting lipolysis and favoring lipid storage (PubMed:18334488, PubMed:19843876, PubMed:20049731, PubMed:23399566). Localizes on the lipid droplet surface, at focal contact sites between lipid droplets, and medi

LOCALIZAÇÃO

Lipid dropletEndoplasmic reticulumNucleus

VIAS BIOLÓGICAS (2)
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosisLipid particle organization
OUTRAS DOENÇAS (1)
CIDEC-related familial partial lipodystrophy
HGNC:24229UniProt:Q96AQ7
PCYT1ACholine-phosphate cytidylyltransferase ADisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the key rate-limiting step in the CDP-choline pathway for phosphatidylcholine biosynthesis

LOCALIZAÇÃO

Cytoplasm, cytosolMembraneEndoplasmic reticulum membraneNucleus

VIAS BIOLÓGICAS (1)
Synthesis of PC
MECANISMO DE DOENÇA

Spondylometaphyseal dysplasia with cone-rod dystrophy

An autosomal recessive disorder characterized by postnatal growth deficiency resulting in profound short stature, rhizomelia with bowing of the lower extremities, platyspondyly with anterior vertebral protrusions, progressive metaphyseal irregularity and cupping with shortened tubular bones, and early-onset progressive visual impairment associated with a pigmentary maculopathy and electroretinographic evidence of cone-rod dysfunction.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Skin Sun Exposed Lower leg
46.6 TPM
Fibroblastos
42.5 TPM
Skin Not Sun Exposed Suprapubic
42.3 TPM
Tecido adiposo
35.0 TPM
Nervo tibial
34.7 TPM
OUTRAS DOENÇAS (3)
spondylometaphyseal dysplasia-cone-rod dystrophy syndromelipodystrophy, congenital generalized, type 5Leber congenital amaurosis
HGNC:8754UniProt:P49585
PLAAT3Phospholipase A and acyltransferase 3Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Exhibits both phospholipase A1/2 and acyltransferase activities (PubMed:19047760, PubMed:19615464, PubMed:22605381, PubMed:22825852, PubMed:26503625). Shows phospholipase A1 (PLA1) and A2 (PLA2) activity, catalyzing the calcium-independent release of fatty acids from the sn-1 or sn-2 position of glycerophospholipids (PubMed:19047760, PubMed:19615464, PubMed:22605381, PubMed:22825852, PubMed:22923616). For most substrates, PLA1 activity is much higher than PLA2 activity (PubMed:19615464). Shows O

LOCALIZAÇÃO

Cell membraneCytoplasmCytoplasm, cytosolCytoplasm, perinuclear regionPeroxisome membraneMitochondrion membraneNucleus envelopeLysosome membraneEndoplasmic reticulum membrane

VIAS BIOLÓGICAS (4)
Acyl chain remodelling of PIAcyl chain remodelling of PCAcyl chain remodelling of PEAcyl chain remodelling of PS
MECANISMO DE DOENÇA

Lipodystrophy, familial partial, 9

An autosomal recessive form of partial lipodystrophy, a disorder characterized by abnormal subcutaneous fat distribution. FPLD9 patients are lean and show muscular hypertrophy, insulin-resistant diabetes with hyperinsulinemia, hypertriglyceridemia with low high-density lipoprotein (HDL) cholesterol, liver steatosis, and polycystic ovary syndrome with hirsutism. Some patients have more generalized lipoatrophy, whereas others have abnormal fat accumulation in the face and neck regions and show cushingoid or acromegalic facial features. Most patients also have neurologic features, including demyelinating polyneuropathy, developmental delay and intellectual disability.

OUTRAS DOENÇAS (1)
lipodystrophy, familial partial, type 9
HGNC:17825UniProt:P53816
CAV1Caveolin-1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

May act as a scaffolding protein within caveolar membranes (PubMed:11751885). Forms a stable heterooligomeric complex with CAV2 that targets to lipid rafts and drives caveolae formation. Mediates the recruitment of CAVIN proteins (CAVIN1/2/3/4) to the caveolae (PubMed:19262564). Interacts directly with G-protein alpha subunits and can functionally regulate their activity (By similarity). Involved in the costimulatory signal essential for T-cell receptor (TCR)-mediated T-cell activation. Its bind

LOCALIZAÇÃO

Golgi apparatus membraneCell membraneMembrane, caveolaMembrane raftGolgi apparatus, trans-Golgi networkCytoplasm

VIAS BIOLÓGICAS (4)
SARS-CoV-2 targets host intracellular signalling and regulatory pathwaysSARS-CoV-1 targets host intracellular signalling and regulatory pathwaysExtra-nuclear estrogen signalingBasigin interactions
MECANISMO DE DOENÇA

Lipodystrophy, congenital generalized, 3

A form of congenital generalized lipodystrophy, a metabolic disorder characterized by a near complete absence of adipose tissue, extreme insulin resistance, hypertriglyceridemia, hepatic steatosis and diabetes mellitus. CGL3 inheritance is autosomal recessive.

OUTRAS DOENÇAS (6)
pulmonary hypertension, primary, 3partial lipodystrophy, congenital cataracts, and neurodegeneration syndromecongenital generalized lipodystrophy type 3heritable pulmonary arterial hypertension
HGNC:1527UniProt:Q03135
ZMPSTE24CAAX prenyl protease 1 homologDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Transmembrane metalloprotease whose catalytic activity is critical for processing lamin A/LMNA on the inner nuclear membrane and clearing clogged translocons on the endoplasmic reticulum (PubMed:33293369, PubMed:33315887). Proteolytically removes the C-terminal three residues of farnesylated proteins (PubMed:33293369, PubMed:33315887). Also plays an antiviral role independently of its protease activity by restricting enveloped RNA and DNA viruses, including influenza A, Zika, Ebola, Sindbis, ves

LOCALIZAÇÃO

Endoplasmic reticulum membraneNucleus inner membraneEarly endosome membraneLate endosome membrane

MECANISMO DE DOENÇA

Mandibuloacral dysplasia with type B lipodystrophy

A form of mandibuloacral dysplasia, a rare progeroid disorder with clinical and genetic heterogeneity, characterized by growth retardation, craniofacial dysmorphic features due to distal bone resorption, musculoskeletal and skin abnormalities associated with lipodystrophy. MADB is a disease characterized by mandibular and clavicular hypoplasia, acroosteolysis, delayed closure of the cranial suture, joint contractures, and generalized lipodystrophy with loss of subcutaneous fat from the extremities, face, neck and trunk.

EXPRESSÃO TECIDUAL(Ubíquo)
Aorta
70.8 TPM
Fibroblastos
63.2 TPM
Útero
58.5 TPM
Fallopian Tube
49.5 TPM
Artéria coronária
43.6 TPM
OUTRAS DOENÇAS (4)
mandibuloacral dysplasia with type B lipodystrophyrestrictive dermopathy 1restrictive dermopathyHutchinson-Gilford progeria syndrome
HGNC:12877UniProt:O75844
KCNJ6G protein-activated inward rectifier potassium channel 2Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium. This potassium channel may be involved in the regulation of insulin

LOCALIZAÇÃO

Membrane

VIAS BIOLÓGICAS (2)
Activation of G protein gated Potassium channelsInhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits
MECANISMO DE DOENÇA

Keppen-Lubinsky syndrome

A rare disease characterized by severe developmental delay, intellectual disability, severe generalized lipodystrophy, dysmorphic features including microcephaly, large prominent eyes, narrow nasal bridge, tented upper lip, high palate, open mouth, tightly adherent skin, and aged appearance.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cérebro - Hemisfério cerebelar
8.3 TPM
Cerebelo
7.5 TPM
Brain Frontal Cortex BA9
4.8 TPM
Córtex cerebral
4.2 TPM
Pituitária
3.8 TPM
OUTRAS DOENÇAS (1)
Keppen-Lubinsky syndrome
HGNC:6267UniProt:P48051
PIK3R1Phosphatidylinositol 3-kinase regulatory subunit alphaDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Binds to activated (phosphorylated) protein-Tyr kinases, through its SH2 domain, and acts as an adapter, mediating the association of the p110 catalytic unit to the plasma membrane. Necessary for the insulin-stimulated increase in glucose uptake and glycogen synthesis in insulin-sensitive tissues. Plays an important role in signaling in response to FGFR1, FGFR2, FGFR3, FGFR4, KITLG/SCF, KIT, PDGFRA and PDGFRB. Likewise, plays a role in ITGB2 signaling (PubMed:17626883, PubMed:19805105, PubMed:75

LOCALIZAÇÃO

VIAS BIOLÓGICAS (5)
PI5P, PP2A and IER3 Regulate PI3K/AKT SignalingPIP3 activates AKT signalingConstitutive Signaling by Aberrant PI3K in CancerPI3K events in ERBB2 signalingAntigen activates B Cell Receptor (BCR) leading to generation of second messengers
MECANISMO DE DOENÇA

Agammaglobulinemia 7, autosomal recessive

A primary immunodeficiency characterized by profoundly low or absent serum antibodies and low or absent circulating B-cells due to an early block of B-cell development. Affected individuals develop severe infections in the first years of life.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
154.4 TPM
Esôfago - Muscular
89.5 TPM
Esôfago - Junção
83.7 TPM
Mama
82.2 TPM
Útero
78.3 TPM
OUTRAS DOENÇAS (4)
SHORT syndromeimmunodeficiency 36 with lymphoproliferationagammaglobulinemia 7, autosomal recessiveautosomal agammaglobulinemia
HGNC:8979UniProt:P27986
PPARGPeroxisome proliferator-activated receptor gammaDisease-causing germline mutation(s) inModerado
FUNÇÃO

Ligand-activated transcription factor that forms obligate heterodimers with the retinoic acid receptor and acts as a key regulator of biological processes, such as adipocyte differentiation, lipid metabolism, glucose homeostasis and beta-oxidation of fatty acids (PubMed:16150867, PubMed:20829347, PubMed:23525231, PubMed:8702406, PubMed:8706692, PubMed:9065481). Activated by lipid ligands: binds peroxisome proliferators, such as hypolipidemic drugs, and fatty acids, such as prostaglandin J2 metab

LOCALIZAÇÃO

NucleusCytoplasm

VIAS BIOLÓGICAS (7)
Regulation of PTEN gene transcriptionTranscriptional regulation of white adipocyte differentiationPPARA activates gene expressionMECP2 regulates transcription factorsNuclear Receptor transcription pathway
EXPRESSÃO TECIDUAL(Ubíquo)
Tecido adiposo
111.2 TPM
Adipose Visceral Omentum
100.8 TPM
Mama
71.3 TPM
Cólon transverso
21.6 TPM
Fibroblastos
20.4 TPM
OUTRAS DOENÇAS (6)
type 2 diabetes mellitusPPARG-related familial partial lipodystrophyinherited obesitygliosarcoma
HGNC:9236UniProt:P37231
LMNAPrelamin-A/CDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Lamins are intermediate filament proteins that assemble into a filamentous meshwork, and which constitute the major components of the nuclear lamina, a fibrous layer on the nucleoplasmic side of the inner nuclear membrane (PubMed:10080180, PubMed:10580070, PubMed:10587585, PubMed:10814726, PubMed:11799477, PubMed:12075506, PubMed:12927431, PubMed:15317753, PubMed:18551513, PubMed:18611980, PubMed:2188730, PubMed:22431096, PubMed:2344612, PubMed:23666920, PubMed:24741066, PubMed:31434876, PubMed:

LOCALIZAÇÃO

Nucleus laminaNucleus envelopeNucleus, nucleoplasmNucleus matrixNucleus speckle

VIAS BIOLÓGICAS (1)
Initiation of Nuclear Envelope (NE) Reformation
MECANISMO DE DOENÇA

Emery-Dreifuss muscular dystrophy 2, autosomal dominant

A form of Emery-Dreifuss muscular dystrophy, a degenerative myopathy characterized by weakness and atrophy of muscle without involvement of the nervous system, early contractures of the elbows, Achilles tendons and spine, and cardiomyopathy associated with cardiac conduction defects.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
392.7 TPM
Aorta
300.6 TPM
Skin Not Sun Exposed Suprapubic
297.7 TPM
Skin Sun Exposed Lower leg
272.6 TPM
Útero
255.8 TPM
OUTRAS DOENÇAS (23)
restrictive dermopathy 2familial partial lipodystrophy, Dunnigan typedilated cardiomyopathy-hypergonadotropic hypogonadism syndromemandibuloacral dysplasia with type A lipodystrophy
HGNC:6636UniProt:P02545
BSCL2SeipinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Plays a crucial role in the formation of lipid droplets (LDs) which are storage organelles at the center of lipid and energy homeostasis (PubMed:19278620, PubMed:21533227, PubMed:30293840, PubMed:31708432). In association with LDAF1, defines the sites of LD formation in the ER (PubMed:31708432). Also required for growth and maturation of small nascent LDs into larger mature LDs (PubMed:27564575). Mediates the formation and/or stabilization of endoplasmic reticulum-lipid droplets (ER-LD) contacts

LOCALIZAÇÃO

Endoplasmic reticulum membraneLipid droplet

MECANISMO DE DOENÇA

Lipodystrophy, congenital generalized, 2

A form of congenital generalized lipodystrophy, a metabolic disorder characterized by a near complete absence of adipose tissue, extreme insulin resistance, hypertriglyceridemia, hepatic steatosis and early onset of diabetes. Inheritance is autosomal recessive.

OUTRAS DOENÇAS (5)
hereditary spastic paraplegia 17severe neurodegenerative syndrome with lipodystrophyneuronopathy, distal hereditary motor, type 5Ccongenital generalized lipodystrophy type 2
HGNC:15832UniProt:Q96G97

Variantes genéticas (ClinVar)

501 variantes patogênicas registradas no ClinVar.

🧬 PLIN1: GRCh37/hg19 15q24.1-26.3(chr15:73506509-102429112)x3 ()
🧬 PLIN1: NM_002666.5(PLIN1):c.1223C>A (p.Ser408Ter) ()
🧬 PLIN1: NM_002666.5(PLIN1):c.203_218del (p.Leu68fs) ()
🧬 PLIN1: NC_000015.9:g.(?_89379429)_(91312836_?)del ()
🧬 PLIN1: NM_002666.5(PLIN1):c.277C>T (p.Arg93Ter) ()
Ver todas no ClinVar

Vias biológicas (Reactome)

130 vias biológicas associadas aos genes desta condição.

Triglyceride catabolism Transcriptional regulation of white adipocyte differentiation NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis Activation of BAD and translocation to mitochondria PIP3 activates AKT signaling Downregulation of ERBB2:ERBB3 signaling Translocation of SLC2A4 (GLUT4) to the plasma membrane Activation of AKT2 PDE3B signalling Inhibition of TSC complex formation by PKB AKT phosphorylates targets in the cytosol AKT phosphorylates targets in the nucleus Negative regulation of the PI3K/AKT network AKT-mediated inactivation of FOXO1A Deactivation of the beta-catenin transactivating complex CD28 dependent PI3K/Akt signaling Co-inhibition by CTLA4 G beta:gamma signalling through PI3Kgamma VEGFR2 mediated vascular permeability TP53 Regulates Metabolic Genes Constitutive Signaling by AKT1 E17K in Cancer Regulation of TP53 Degradation Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors Cyclin E associated events during G1/S transition Cyclin A:Cdk2-associated events at S phase entry RAB GEFs exchange GTP for GDP on RABs RUNX2 regulates genes involved in cell migration Regulation of PTEN stability and activity FLT3 Signaling Regulation of localization of FOXO transcription factors Estrogen-dependent nuclear events downstream of ESR-membrane signaling KEAP1-NFE2L2 pathway Cytosolic sensors of pathogen-associated DNA RNA Polymerase III Chain Elongation RNA Polymerase III Transcription Termination RNA Polymerase III Abortive And Retractive Initiation RNA Polymerase III Transcription Initiation From Type 1 Promoter RNA Polymerase III Transcription Initiation From Type 2 Promoter RNA Polymerase III Transcription Initiation From Type 3 Promoter Pre-NOTCH Processing in the Endoplasmic Reticulum Pre-NOTCH Transcription and Translation Pre-NOTCH Processing in Golgi Notch-HLH transcription pathway Defective LFNG causes SCDO3 NOTCH3 Activation and Transmission of Signal to the Nucleus NOTCH3 Intracellular Domain Regulates Transcription Noncanonical activation of NOTCH3 RNA Polymerase I Transcription Termination RHOA GTPase cycle RHOB GTPase cycle RHOC GTPase cycle Synthesis of PA Neutrophil degranulation Adrenoceptors Adrenaline signalling through Alpha-2 adrenergic receptor Adrenaline,noradrenaline inhibits insulin secretion G alpha (i) signalling events G alpha (z) signalling events Surfactant metabolism Assembly of active LPL and LIPC lipase complexes Lipid particle organization Synthesis of PC eNOS activation NOSTRIN mediated eNOS trafficking Thyroxine biosynthesis Basigin interactions Disassembly of the destruction complex and recruitment of AXIN to the membrane Extra-nuclear estrogen signaling CDC42 GTPase cycle RAC1 GTPase cycle RAC2 GTPase cycle RHOD GTPase cycle RHOQ GTPase cycle RHOH GTPase cycle RHOG GTPase cycle RHOJ GTPase cycle RAC3 GTPase cycle RHOF GTPase cycle FOXO-mediated transcription of cell cycle genes RND3 GTPase cycle RND2 GTPase cycle RND1 GTPase cycle SARS-CoV-1 targets host intracellular signalling and regulatory pathways SARS-CoV-2 targets host intracellular signalling and regulatory pathways Activation of G protein gated Potassium channels Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits PI3K Cascade IRS-mediated signalling GPVI-mediated activation cascade Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K events in ERBB4 signaling Interleukin-7 signaling Signaling by SCF-KIT Synthesis of PIPs at the plasma membrane GAB1 signalosome Signaling by cytosolic FGFR1 fusion mutants Downstream signal transduction PI3K events in ERBB2 signaling PI3K/AKT activation Signaling by ALK Downstream TCR signaling Role of phospholipids in phagocytosis Tie2 Signaling Constitutive Signaling by Aberrant PI3K in Cancer DAP12 signaling Role of LAT2/NTAL/LAB on calcium mobilization Nephrin family interactions G alpha (q) signalling events GP1b-IX-V activation signalling VEGFA-VEGFR2 Pathway Interleukin-3, Interleukin-5 and GM-CSF signaling Constitutive Signaling by EGFRvIII PI-3K cascade:FGFR1 PI-3K cascade:FGFR2 PPARA activates gene expression Nuclear Receptor transcription pathway SUMOylation of intracellular receptors Regulation of PTEN gene transcription MECP2 regulates transcription factors Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 Meiotic synapsis Nuclear Envelope Breakdown Initiation of Nuclear Envelope (NE) Reformation Breakdown of the nuclear lamina XBP1(S) activates chaperone genes Depolymerization of the Nuclear Lamina Signaling by BRAF and RAF1 fusions Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
3Fase 31
2Fase 21
·Pré-clínico3
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 5 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Lipodistrofia genética

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

2 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

0 ensaios clínicos encontrados.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
17 papers (10 anos)
#1

The Role of the AGPAT2 Gene in Adipose Tissue Biology and Congenital Generalized Lipodystrophy Pathophysiology.

International journal of molecular sciences2025 Jun 05

O gene AGPAT2 é crucial para o desenvolvimento do tecido adiposo e sua função, e mutações nele causam a Lipodistrofia Generalizada Congênita tipo 1 (CGL1). Pacientes com CGL1 nascem sem gordura corporal e enfrentam sérias complicações metabólicas, como diabetes e triglicerídeos altos. Este estudo utiliza ferramentas bioinformáticas para analisar o impacto de variantes genéticas específicas no AGPAT2, correlacionando-as com o quadro clínico e metabólico dos pacientes para melhorar a compreensão da doença e a relação entre genótipo e fenótipo.

🇧🇷 traduzido
#2

Calf skinfold measurements as a diagnostic tool for lipodystrophy syndromes: a cross-sectional study.

Diabetology & metabolic syndrome2025 Oct 10

As síndromes de lipodistrofia genética são complexas de diagnosticar e frequentemente acarretam complicações metabólicas sérias, como resistência à insulina e diabetes. Este estudo identificou que a medição da dobra cutânea da panturrilha, com um corte de <8mm, é uma ferramenta diagnóstica precisa para as lipodistrofias generalizada congênita (CGL) e parcial familiar (FPL). Sua acessibilidade clínica favorece a ampla utilização e inclusão em protocolos de exame físico, melhorando significativamente a detecção e o diagnóstico precoce dessas condições para pacientes e médicos.

🇧🇷 traduzido
#3

Diagnosis and Management of Genetic Lipodystrophy Syndromes and its Implications for Atherosclerosis.

Current atherosclerosis reports2025 May 13

As lipodistrofias genéticas são síndromes caracterizadas por distribuição anormal de gordura e complicações metabólicas significativas, frequentemente mal diagnosticadas como diabetes tipo 2. É crucial que médicos e pacientes compreendam que essas condições estão associadas a um alto risco de doenças cardiovasculares e aterosclerose precoce. Assim, um alto nível de suspeita para o diagnóstico precoce e manejo eficaz é essencial para mitigar esses riscos e melhorar os resultados de saúde.

🇧🇷 traduzido
#4

Lipodystrophy and severe insulin resistance syndrome: Epidemiological data from a French national rare diseases registry.

Annales d'endocrinologie2025 Jul

Este estudo francês destaca que a lipodistrofia genética e a síndrome de resistência à insulina severa, embora raras, estão significativamente subdiagnosticadas, com um aumento recente na prevalência estimada devido à melhoria das ferramentas epidemiológicas. Para pacientes e médicos, é crucial reconhecer os longos atrasos no diagnóstico – especialmente para a lipodistrofia parcial (até 18 anos) – e as disparidades regionais e de gênero. Maior conhecimento sobre estas doenças é essencial para acelerar o diagnóstico e melhorar o manejo.

🇧🇷 traduzido
#5

Health-related Quality of Life, Social, and Psychological Well-Being of 109 Adult Patients With Genetic Lipodystrophy.

The Journal of clinical endocrinology and metabolism2025 Jul 15

Este estudo revela que pacientes com lipodistrofia genética sofrem uma qualidade de vida significativamente reduzida, com alta incidência de depressão, dor crônica e impacto negativo na imagem corporal. Um achado crucial é a alta prevalência de discriminação social (73%), com um terço vindo de profissionais de saúde. Para pacientes e médicos, isso sublinha a necessidade urgente de suporte psicossocial integrado e de programas terapêuticos educativos específicos para abordar tanto os sintomas físicos quanto os psicológicos.

🇧🇷 traduzido

Publicações recentes

Ver todas no PubMed

📚 EuropePMC6 artigos no totalmostrando 16

2025

Calf skinfold measurements as a diagnostic tool for lipodystrophy syndromes: a cross-sectional study.

Diabetology &amp; metabolic syndrome
2025

The Role of the AGPAT2 Gene in Adipose Tissue Biology and Congenital Generalized Lipodystrophy Pathophysiology.

International journal of molecular sciences
2025

Diagnosis and Management of Genetic Lipodystrophy Syndromes and its Implications for Atherosclerosis.

Current atherosclerosis reports
2025

Lipodystrophy and severe insulin resistance syndrome: Epidemiological data from a French national rare diseases registry.

Annales d'endocrinologie
2024

Corrigendum: Familial partial lipodystrophy resulting from loss-of-function PPARγ pathogenic variants: phenotypic, clinical, and genetic features.

Frontiers in endocrinology
2025

Health-related Quality of Life, Social, and Psychological Well-Being of 109 Adult Patients With Genetic Lipodystrophy.

The Journal of clinical endocrinology and metabolism
2024

Familial partial lipodystrophy resulting from loss-of-function PPARγ pathogenic variants: phenotypic, clinical, and genetic features.

Frontiers in endocrinology
2024

Patients' perspective on the medical pathway from first symptoms to diagnosis in genetic lipodystrophy.

European journal of endocrinology
2024

Lipodystrophy as a target to delay premature aging.

Trends in endocrinology and metabolism: TEM
2022

PPARγ Gene as a Possible Link between Acquired and Congenital Lipodystrophy and its Modulation by Dietary Fatty Acids.

Nutrients
2020

Acromegaly with congenital generalized lipodystrophy - two rare insulin resistance conditions in one patient: a case report.

Journal of medical case reports
2020

High prevalence of mutations in perilipin 1 in patients with precocious acute coronary syndrome.

Atherosclerosis
2020

A novel autosomal recessive lipodystrophy syndrome due to homozygous LMNA variant.

Journal of medical genetics
2019

Body Composition and Genetic Lipodystrophy Risk Score Associate With Nonalcoholic Fatty Liver Disease and Liver Fibrosis.

Hepatology communications
2020

Pathologic fracture revealed a rare syndromic form of genetic lipodystrophy.

Clinical dysmorphology
2016

Bone imaging findings in genetic and acquired lipodystrophic syndromes: an imaging study of 24 cases.

Skeletal radiology

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Lipodistrofia genética.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Lipodistrofia genética

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. The Role of the AGPAT2 Gene in Adipose Tissue Biology and Congenital Generalized Lipodystrophy Pathophysiology.
    International journal of molecular sciences· 2025· PMID 40508223mais citado
  2. Calf skinfold measurements as a diagnostic tool for lipodystrophy syndromes: a cross-sectional study.
    Diabetology &amp; metabolic syndrome· 2025· PMID 41074178mais citado
  3. Diagnosis and Management of Genetic Lipodystrophy Syndromes and its Implications for Atherosclerosis.
    Current atherosclerosis reports· 2025· PMID 40358796mais citado
  4. Lipodystrophy and severe insulin resistance syndrome: Epidemiological data from a French national rare diseases registry.
    Annales d'endocrinologie· 2025· PMID 40174859mais citado
  5. Health-related Quality of Life, Social, and Psychological Well-Being of 109 Adult Patients With Genetic Lipodystrophy.
    The Journal of clinical endocrinology and metabolism· 2025· PMID 39657019mais citado
  6. Editorial: Improving diagnosis and management of genetic lipodystrophy.
    Front Endocrinol (Lausanne)· 2024· PMID 39916752recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:98305(Orphanet)
  2. MONDO:0020087(MONDO)
  3. GARD:12597(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q55789109(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Lipodistrofia genética
Compêndio · Raras BR

Lipodistrofia genética

ORPHA:98305 · MONDO:0020087
CID-11
MedGen
UMLS
C4511302
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades